Evolus
Evolus' revenue rose 11.6% to $297 million in fiscal 2025. Its operating margin was −11.0%, up from −12.9% a year earlier. Free cash flow was −$46 million. The diluted share count rose 4.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Evolus does
Evolus sells aesthetic products that people pay for out of pocket, not through insurance. Its customers are licensed aesthetic practitioners, who inject its products. It focuses on two large categories of cosmetic injectables: neurotoxins and hyaluronic acid gels.
Its first product, Jeuveau, is a botulinum toxin type A product that temporarily improves the look of moderate to severe frown lines between the eyebrows in adults. It positions it as an alternative to BOTOX. Jeuveau is sold in the United States, Canada, certain European markets and Australia. Its second line, Evolysse, is a set of injectable hyaluronic acid gels for wrinkles and folds. The FDA approved the first two in February 2025, and they launched in the U.S. in April 2025. Evolus expects to launch all four in Europe in the second quarter of 2026 and to add two more in the U.S.
Evolus uses programs such as a consumer loyalty program, co-branded marketing and promotions to win customers. It depends on Symatese for approval of Evolysse in the United States.
Its biggest risks, as it describes them
- It has lost money since it started and may keep losing money.
- Its products face tough competition and may not win enough use by practitioners or demand from consumers.
- Its sales depend on consumer discretionary spending, and on tariffs and other trade changes.
- It relies on Symatese to win and keep U.S. approval for the Evolysse line.
- It may need more financing, and must follow a settlement agreement with Medytox.
Income statement
Evolus lost money in fiscal 2025: a net loss of $52 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 146 | 54 | 63 | 87 | 54 |
| Debt incl. finance leases | 71 | 72 | 120 | 122 | 146 |
| Net debt (negative means net cash) | −75 | 18 | 58 | 34 | 92 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.9x | 3.9x | — | — | — |
| Interest coverage | −31.8x | −7.2x | −3.6x | −1.8x | −1.7x |
| Current ratio | 3.1x | 2.2x | 2.3x | 2.4x | 1.9x |
| Quick ratio | 3.1x | 1.8x | 2.1x | 2.2x | 1.5x |
Cash flow
Projections
Project Evolus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Evolus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 2 of 9 |
| Rule of 40 | 18.9% | 24.4% | −3.8% |
| Altman Z'' | −9.27 | −7.02 | −8.65 |
| Accruals ratio | −15.1% | −15.4% | −4.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 4 of 9 | 6 of 9 | 2 of 9 |
Compare
Put Evolus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
| CorMedix | FY25 | 617.0% | 48.2% | 55.4% | — | −0.9x | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | 0 | 35 | 56 | 100 | 149 | 202 | 266 | 297 |
| Revenue growth | — | — | — | 61.9% | 76.3% | 49.1% | 36.0% | 31.8% | 11.6% |
| Gross profit | — | 0 | 27 | 38 | 56 | 90 | 138 | 182 | 197 |
| Research and development | 7 | 6 | 4 | 2 | 2 | 5 | 7 | 9 | 10 |
| Operating income | −12 | −46 | −99 | −153 | −44 | −65 | −49 | −34 | −33 |
| Net income | −4 | −47 | −90 | −163 | −47 | −74 | −62 | −50 | −52 |
| Diluted EPS (US$) | −0.27 | −1.92 | −3.19 | −4.83 | −0.94 | −1.33 | −1.08 | −0.81 | −0.80 |
| Diluted shares (millions) | 16 | 24 | 28 | 34 | 50 | 56 | 57 | 62 | 64 |
| Cash flow | |||||||||
| Cash from operations | −13 | −26 | −93 | −58 | −33 | −85 | −34 | −18 | −42 |
| Capital expenditure | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 3 |
| Free cash flow | −13 | −26 | −94 | −59 | −34 | −87 | −34 | −19 | −46 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 7 | 10 | 11 | 10 | 11 | 16 | 22 | 21 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 0 | 93 | 130 | 108 | 146 | 54 | 63 | 87 | 54 |
| Debt incl. finance leases | 139 | 0 | 74 | 40 | 71 | 72 | 120 | 122 | 146 |
| Total assets | 152 | 172 | 240 | 209 | 258 | 178 | 189 | 233 | 226 |
| Total liabilities | 228 | 88 | 161 | 282 | 176 | 160 | 210 | 227 | 249 |
| Shareholders' equity | −76 | 84 | 80 | −73 | 82 | 18 | −21 | 6 | −23 |
| Margins and ratios | |||||||||
| Gross margin | — | — | 77.0% | 67.6% | 56.3% | 60.4% | 68.1% | 68.5% | 66.3% |
| Operating margin | — | — | −283.3% | −270.7% | −44.5% | −44.0% | −24.4% | −12.9% | −11.0% |
| Net margin | — | — | −257.8% | −288.3% | −47.0% | −50.1% | −30.5% | −18.9% | −17.4% |
| Free cash flow margin | — | — | −268.4% | −103.8% | −33.9% | −58.2% | −17.1% | −7.3% | −15.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | −41.9% | 42.4% | −9.1% | 18.9% | 24.4% | −3.8% |
| Return on capital | — | −134.1% | — | — | — | — | −106.1% | −70.7% | −47.2% |
| Return on equity | — | — | −109.9% | — | — | −148.3% | — | — | — |
| Return on assets | — | −28.9% | −43.7% | −72.5% | −20.1% | −34.2% | −33.6% | −23.9% | −22.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |